Holen Sie sich die Stockscreener-App
5.18
3.81%
0.19
Handel nachbörslich:
5.08
-0.10
-1.93%
Schlusskurs vom Vortag:
$4.99
Offen:
$4.99
24-Stunden-Volumen:
61,356
Relative Volume:
0.28
Marktkapitalisierung:
$42.36M
Einnahmen:
$120.77M
Nettoeinkommen (Verlust:
$32.69M
KGV:
1.7773
EPS:
2.9146
Netto-Cashflow:
$-50.94M
1W Leistung:
-1.15%
1M Leistung:
+5.50%
6M Leistung:
-64.59%
1J Leistung:
-23.15%
1-Tages-Spanne:
$4.99
$5.30
1-Wochen-Bereich:
$4.91
$5.5472
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
5.18 | 40.81M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
437.67 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.58 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.22 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.58 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.41 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - The Malaysian Reserve
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money H - GuruFocus
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Robbins LLP Urges ATRA Stockholders to Contact the Firm for - GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara Biotherapeutics, Inc. Securities Lawsuit — The Gross Law Firm - Morningstar
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Atara Biotherapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - The Killeen Daily Herald
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REMINDER: Atara Biotherapeutics, Inc. Investors With Significant Losses Must Act By May 22, 2026 – Contact Kirby McInerney LLP - Business Wire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff - GlobeNewswire
ATRA Stockholders Have RightsIf You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses - PR Newswire
Atara Biotherapeutics Faces Securities Lawsuit After FDA Setbacks and Sharp Stock Declines Tied to Tabelecleucel - TipRanks
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - GuruFocus
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - ChartMill
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - ChartMill
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-04-16 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel ... - Caledonian Record
ROSEN, A LEADING LAW FIRM, Encourages Atara - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - ChartMill
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
2026-04-14 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Press releases provided by CNW - Techaeris
Class Action Filed Against Atara Biotherapeutics Over Alleged Securities Fraud - National Today
Class Action Filed Against Atara Biotherapeutics, Inc. (ATRA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Atara Biotherapeutics Faces Securities Fraud Lawsuit - National Today
Activity Recap: Is Atara Biotherapeutics Inc impacted by rising ratesMarket Trend Summary & Verified Technical Signals - baoquankhu1.vn
Buybacks Report: What are analysts price targets for Atara Biotherapeutics IncInsider Selling & Precise Trade Entry Recommendations - baoquankhu1.vn
Atara Biotherapeutics, Inc.Common Stock (NQ: ATRA - The Chronicle-Journal
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Mar 02 '26 |
Sale |
5.08 |
2,104 |
10,691 |
31,750 |
| Nguyen AnhCo | President and CEO |
Mar 02 '26 |
Sale |
5.09 |
2,996 |
15,237 |
61,978 |
2.53%
2.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):